FearLess in Cognitively Intact Patients With Glioma

NCT05604365•Virginia Commonwealth University

Summary

This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patient inclusion:
•Confirmed glioma diagnosis (grade II-IV) via histopathology
•Be a minimum of 2 weeks post surgical repair or biopsy (if applicable)
•Elevated FCR \[\> 13 on Fear of Cancer Recurrence Inventory\]
•Primarily English speaking
•Caregiver Inclusion:
•Loved one, or non-paid care partner to a patient with a confirmed glioma diagnosis (grade II-IV) via histopathology
•Elevated FCR \[\> 13 on Fear of Cancer Recurrence Inventory\]
•Primarily English speaking
•Age 18+

Exclusion Criteria

•Patient:
•Cognitive impairment \[\< or equal to 31 on the Telephone Interview for Cognitive Status (TICS)\]
•Inability to attend virtual sessions (e.g. due to lack of stable internet connection, difficulty using technology)
•Inability to understand and provide informed consent.
•Caregiver:
•Inability to attend virtual sessions (e.g. due to lack of stable internet connection, difficulty using technology)
•Inability to understand and provide informed consent.

Locations (1)

Virginia Commonwealth University

Richmond, Virginia, United States

Key Dates

Start Date

November 7, 2022

Primary Completion Date

November 14, 2023

Completion Date

November 14, 2023

Last Updated

February 9, 2024

Enrollment

ACTUAL participants

Conditions

GliomaFear of Cancer

Interventions

FearLess Intervention

BEHAVIORAL

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITING

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

FearLess in Cognitively Intact Patients With Glioma

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Targeted Pediatric High-Grade Glioma Therapy

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors